Precision BioSciences, Inc. (DTIL) News

Precision BioSciences, Inc. (DTIL): $1.71

-0.02 (-1.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DTIL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter DTIL News Items

DTIL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DTIL News Highlights

  • DTIL's 30 day story count now stands at 6.
  • Over the past 16 days, the trend for DTIL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about DTIL are AGE, GENE and MRNA.

Latest DTIL News From Around the Web

Below are the latest news stories about Precision Biosciences Inc that investors may wish to consider to help them evaluate DTIL as an investment opportunity.

Executive voice: New leader joins Durham biotech chasing permanent cures

A personal experience at a young age inspired Michael Amoroso’s career in health care. Now, he's at the helm of a Durham company developing new treatments.

Yahoo | February 24, 2022

Moderna (MRNA) Beats Q4 Earnings and Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 14.85% and 7.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

What to Expect From Precision BioSciences (DTIL) Q4 Earnings

On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.

Yahoo | February 22, 2022

Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should Know

Precision BioSciences (DTIL) closed the most recent trading day at $4.82, moving -0.62% from the previous trading session.

Yahoo | February 16, 2022

A Potential 10X Biotech Play

Gene therapy saves a life … a small biotech that could be a 10X winner … keep your eyes on the entire biotech sector for great set-ups over the coming quarters Paddy Doherty’s father was in his 60s when he began getting breathless on walks. Doctors believed it was angina, but two years later when Doherty’s father died of a heart attack, the real culprit was identified – a rare disease called transthyretin (ATTR) amyloidosis. It’s a terrible, progressive health condition that’s ultimately fatal.I

Yahoo | February 9, 2022

Precision BioSciences (DTIL) Gains But Lags Market: What You Should Know

In the latest trading session, Precision BioSciences (DTIL) closed at $4.86, marking a +0.83% move from the previous day.

Yahoo | February 8, 2022

Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D. as General Counsel and Corporate Secretary. Lori Kunkel, M.D. and Ron Dror, Ph.D. have also joined the company's Scientific Advisory Board.

Yahoo | January 25, 2022

Precision BioSciences (NASDAQ:DTIL shareholders incur further losses as stock declines 23% this week, taking one-year losses to 65%

Even the best stock pickers will make plenty of bad investments. And there's no doubt that Precision BioSciences, Inc...

Yahoo | January 24, 2022

Newbridge Financial Services Group, Inc. Buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, ...

Investment company Newbridge Financial Services Group, Inc. (Current Portfolio) buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, Microsoft Corp, Tesla Inc, sells NIO Inc, Lemonade Inc, Alibaba Group Holding, Carnival Corp, Blackstone Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Newbridge Financial Services Group, Inc..

Yahoo | January 19, 2022

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

Yahoo | January 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6029 seconds.